PMID- 30499070
OWN - NLM
STAT- MEDLINE
DCOM- 20200129
LR  - 20200309
IS  - 1970-9366 (Electronic)
IS  - 1828-0447 (Linking)
VI  - 14
IP  - 3
DP  - 2019 Apr
TI  - Safety and efficacy of sucrosomial iron in inflammatory bowel disease patients 
      with iron deficiency anemia.
PG  - 423-431
LID - 10.1007/s11739-018-1993-9 [doi]
AB  - Iron deficiency anemia (IDA) is one of the most common complications of 
      inflammatory bowel disease (IBD). We planned a prospective study to address 
      tolerability and efficacy of sucrosomial iron, a new oral formulation of ferric 
      pyrophosphate, in IBD patients. Thirty patients with a confirmed diagnosis of 
      Crohn's Disease (CD) or ulcerative colitis (UC) and mild IDA were enrolled. 
      Patients with severe IBD were excluded. All patients underwent 12 weeks of oral 
      treatment with 30 mg/day of sucrosomial iron. Treatment compliance and adverse 
      events were investigated every 4 weeks. Iron status, hematological parameters and 
      IBD activity scores were determined at baseline and at the end of treatment, as 
      well as serum hepcidin and non-transferrin bound iron (NTBI) levels. Twenty-four 
      (80%) patients took more than 90% of the prescribed regimen. Forty-four adverse 
      events (AEs) were recorded, but none of them is considered certainly or probably 
      related to the study treatment. Interestingly, only eleven gastrointestinal 
      events were recorded in 9 (30%) patients. At the end of treatment, all iron 
      parameters improved significantly and Hb increased in 86% of patients (from 11.67 
      to 12.37 g/dl, p = 0.001). Serum hepcidin showed a significant increase in 79% of 
      patients and became positively correlated with C-reactive protein (CRP) at the 
      end of the study, while NTBI remained below the detection threshold after iron 
      supplementation. The IBD activity scores improved in both CD and UC. This pilot 
      interventional study supports the therapeutic use of sucrosomial iron in IBD and 
      paves the way for future studies in larger or more difficult IBD populations.
FAU - Abbati, Gianluca
AU  - Abbati G
AD  - Division of Internal Medicine 2 and Center for Hemochromatosis, University of 
      Modena and Reggio Emilia, Via DEL Pozzo 71, 41124, Modena, Italy. 
      abbati.gl@unimore.it.
FAU - Incerti, Federica
AU  - Incerti F
AD  - Division of Internal Medicine 2 and Center for Hemochromatosis, University of 
      Modena and Reggio Emilia, Via DEL Pozzo 71, 41124, Modena, Italy.
FAU - Boarini, Chiara
AU  - Boarini C
AD  - Division of Internal Medicine 2 and Center for Hemochromatosis, University of 
      Modena and Reggio Emilia, Via DEL Pozzo 71, 41124, Modena, Italy.
FAU - Pileri, Francesca
AU  - Pileri F
AD  - Division of Internal Medicine 2 and Center for Hemochromatosis, University of 
      Modena and Reggio Emilia, Via DEL Pozzo 71, 41124, Modena, Italy.
FAU - Bocchi, Davide
AU  - Bocchi D
AD  - Division of Internal Medicine 2 and Center for Hemochromatosis, University of 
      Modena and Reggio Emilia, Via DEL Pozzo 71, 41124, Modena, Italy.
FAU - Ventura, Paolo
AU  - Ventura P
AD  - Division of Internal Medicine 2 and Center for Hemochromatosis, University of 
      Modena and Reggio Emilia, Via DEL Pozzo 71, 41124, Modena, Italy.
FAU - Buzzetti, Elena
AU  - Buzzetti E
AD  - Division of Internal Medicine 2 and Center for Hemochromatosis, University of 
      Modena and Reggio Emilia, Via DEL Pozzo 71, 41124, Modena, Italy.
FAU - Pietrangelo, Antonello
AU  - Pietrangelo A
AD  - Division of Internal Medicine 2 and Center for Hemochromatosis, University of 
      Modena and Reggio Emilia, Via DEL Pozzo 71, 41124, Modena, Italy.
LA  - eng
PT  - Journal Article
DEP - 20181129
PL  - Italy
TA  - Intern Emerg Med
JT  - Internal and emergency medicine
JID - 101263418
RN  - 0 (Hepcidins)
RN  - E1UOL152H7 (Iron)
SB  - IM
CIN - Intern Emerg Med. 2019 Apr;14(3):349-351. PMID: 30721398
MH  - Adult
MH  - Anemia, Iron-Deficiency/*drug therapy/physiopathology
MH  - Colitis, Ulcerative/complications/drug therapy/physiopathology
MH  - Crohn Disease/complications/drug therapy/physiopathology
MH  - Female
MH  - Hepcidins/analysis/blood
MH  - Humans
MH  - Inflammatory Bowel Diseases/*complications/drug therapy
MH  - Iron/*blood
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Severity of Illness Index
OTO - NOTNLM
OT  - Anemia
OT  - Hepcidin
OT  - IBD
OT  - Iron
OT  - Sucrosomial
EDAT- 2018/12/01 06:00
MHDA- 2020/01/30 06:00
CRDT- 2018/12/01 06:00
PHST- 2018/07/20 00:00 [received]
PHST- 2018/11/20 00:00 [accepted]
PHST- 2018/12/01 06:00 [pubmed]
PHST- 2020/01/30 06:00 [medline]
PHST- 2018/12/01 06:00 [entrez]
AID - 10.1007/s11739-018-1993-9 [pii]
AID - 10.1007/s11739-018-1993-9 [doi]
PST - ppublish
SO  - Intern Emerg Med. 2019 Apr;14(3):423-431. doi: 10.1007/s11739-018-1993-9. Epub 
      2018 Nov 29.